These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 12365204)

  • 81. A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.
    Dave V; Yadav RB; Yadav S; Sharma S; Sahu RK; Ajayi AF
    Curr Clin Pharmacol; 2018; 13(4):216-235. PubMed ID: 30360723
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Serial versus sparse sampling in toxicokinetic studies.
    Tse FL; Nedelman JR
    Pharm Res; 1996 Jul; 13(7):1105-8. PubMed ID: 8842053
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME.
    Tornøe CW; Agersø H; Nielsen HA; Madsen H; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Dec; 31(6):441-61. PubMed ID: 16222784
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.
    Sherer EA; Sale ME; Pollock BG; Belani CP; Egorin MJ; Ivy PS; Lieberman JA; Manuck SB; Marder SR; Muldoon MF; Scher HI; Solit DB; Bies RR
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):393-414. PubMed ID: 22767341
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.
    Neely MN; van Guilder MG; Yamada WM; Schumitzky A; Jelliffe RW
    Ther Drug Monit; 2012 Aug; 34(4):467-76. PubMed ID: 22722776
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED.
    Jönsson S; Kjellsson MC; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2004 Aug; 31(4):299-320. PubMed ID: 15563005
    [TBL] [Abstract][Full Text] [Related]  

  • 87. How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.
    Ogungbenro K; Aarons L
    Eur J Clin Pharmacol; 2008 Jul; 64(7):705-13. PubMed ID: 18483725
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Evaluation of type I error rates when modeling ordered categorical data in NONMEM.
    Wählby U; Matolcsi K; Karlsson MO; Jonsson EN
    J Pharmacokinet Pharmacodyn; 2004 Feb; 31(1):61-74. PubMed ID: 15346852
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study.
    Takama H; Tanaka H; Sudo T; Tamura T; Tanigawara Y
    Cancer Chemother Pharmacol; 2001 May; 47(5):404-10. PubMed ID: 11391855
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Improved estimates of mean pharmacokinetic parameters for increased accuracy in dosing and reduced risk to patients.
    Scutt G; Waxman D
    Br J Clin Pharmacol; 2021 Sep; 87(9):3518-3530. PubMed ID: 33565142
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Numerical estimation of the noncompartmental pharmacokinetic parameters variance and coefficient of variation of residence times.
    Purves RD
    J Pharm Sci; 1994 Feb; 83(2):202-5. PubMed ID: 8169789
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Optimal sampling theory: effect of error in a nominal parameter value on bias and precision of parameter estimation.
    Drusano GL; Forrest A; Yuen G; Plaisance K; Leslie J
    J Clin Pharmacol; 1994 Oct; 34(10):967-74. PubMed ID: 7836547
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Population Pharmacokinetics of Digoxin in Duchenne Muscular Dystrophy (DMD) Patients.
    Tateishi M; Ebihara A
    Am J Ther; 1994 Aug; 1(2):144-149. PubMed ID: 11835079
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Use of Clinical Trial Simulations to Compare the Performance of Different Approaches for Population Analyses of Pediatric Pharmacokinetic Data.
    Temrikar Z; Muensterman E; Engelhardt B; Mohamed MF
    J Clin Pharmacol; 2023 Jul; 63(7):859-868. PubMed ID: 36905228
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.
    Bach T; An G
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):581-595. PubMed ID: 33884580
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A note on population pharmacokinetic studies with a single sampling design.
    Narukawa M; Yafune A
    Ther Drug Monit; 2005 Apr; 27(2):111-5. PubMed ID: 15795638
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.
    Yano Y; Beal SL; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2001 Apr; 28(2):171-92. PubMed ID: 11381569
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Evaluation of the estimation and classification performance of NONMEM when applying mixture model for drug clearance.
    Hui KH; Lam TN
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1564-1577. PubMed ID: 34648691
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.
    Wade JR; Kelman AW; Howie CA; Whiting B
    J Pharmacokinet Biopharm; 1993 Apr; 21(2):209-22. PubMed ID: 8229681
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Conditional Non-parametric Bootstrap for Non-linear Mixed Effect Models.
    Comets E; Rodrigues C; Jullien V; Ursino M
    Pharm Res; 2021 Jun; 38(6):1057-1066. PubMed ID: 34075519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.